President Trump’s drug-pricing campaign is gaining corporate participants, but the expansion has yet to settle the central question: whether bold savings projections will translate into lasting relief for patients and taxpayers.

The administration says nine additional pharmaceutical companies will offer discounted medicines to state Medicaid programs, bringing the reported total to 26 companies and roughly 90% of the domestic market. The initiative also relies on TrumpRx, a website launched to connect consumers with discounts on name-brand drugs. Supporters frame the new agreements as evidence that the president’s most-favored-nation strategy is compelling an industry long criticized for high U.S. prices. One conservative account describes the companies’ participation as bolstering Trump’s “affordability pitch.”¹

The administration’s rhetoric is expansive. Trump said the agreements could save Americans “more than $600 billion over a very short period of time,”² while the White House said the companies’ Medicaid commitments would produce billions in savings and that they would invest $19.6 billion in U.S. manufacturing.²

The more skeptical reading focuses on the gap between those projections and the structure of the policy. The agreements are voluntary, and the available account does not specify uniform discounts, penalties for noncompliance or a mechanism for independently verifying the headline savings. That leaves the initiative with two competing narratives: an administration presenting participation as proof that its pressure campaign is working, and critics likely to ask whether commitments to selected discounts can meaningfully reshape prices across the wider market.

Trump said the remaining companies “have no choice,”² but the voluntary design suggests that enforcement—not enrollment—will determine whether the plan becomes a durable pricing reform or mainly an affordability message.